Thromboembolic disease and present oral contraception

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 1, 2003, Pages 45-51

  Belicová, Margita ^a   Lukàč, Bohdan ^a   Dvorský, Jàn ^a   Peter, Galajda ^b   Mokáň, Marián ^a   Kubisz, Peter ^a  

^a Martinska Fakultna Nemocnica   (Slovakia)

^b NONE

Author keywords

Acquired resistance to activated protein C; Deep venous thrombosis; Oral contraceptives; Pulmonary embolism; Thromboembolic events

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; COUMARIN; DESOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTODENE; HEPARIN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0037220494     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900106     Document Type: Article

References (16)

1. Fred HL, Hariharam R. Pulmonary thromboembolism. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine. New York: Churchill Livingstone, 2000:1835.
2. Goldhaber SZ. Pulmonary embolism. In: Braunwald E, ed. Heart Disease. Philadelphia: WB Saunders, 1997:1582.
3. Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 1994;36:423.
4. Nieuwenhuis HK, Albada J, Banga JD. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;2:337.
5. Jordan WM. Pulmonary embolism. Lancet 1961;2:1146.
6. Royal College of Practitioners. Oral contraception and thromboembolic disease. J Gen Coll Practit 1967;13:267.
7. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemost 1997;78:327.
8. Andersen BS, Olsen J, Nielsen GL. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:28.
9. Dvořák K. Steroidní kontracepce Compendium. Praha: Remedia, 1996:331-334,378.
10. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;34:1582.
11. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;34:1575.
12. Rosing J, Tans G, Nicolas F. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third -generation oral contraceptives. Br J Haematol 1997;97:233.
13. Furberg GD. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997;278:477.
14. Girolami A, Prandoni P, Zanardi A. Isolated iliac vein thrombosis during oral contraceptive therapy in three normal women. Clin Appl Thromb Hemost 1997;3:284.
15. Čepický, P, Cibula D, Dvořák K, et al. Doporučení k předpisu kombinované perorální kontracepce (COC). Čes Gynek 2000;4:279.
16. Dahlback B. Inherited thrombophilia: Resistance to activated protein C as a pathogenetic factor of venous thromboembolism. Blood 1995;3:607.